Abstract:e17561 Background: to evaluate the activity and mechanism of rAd-p53 combined with chemotherapeutics in treatment of ATC in vitro and in vivoand clinical therapies. Methods: p53-mutant ATC cells (C643 cells) were received with vehicle, paclitaxel, cisplatin, rAd-p53, paclitaxel combined with cisplatin, and rAd-p53 combined with paclitaxel and cisplatin to evaluate the in vitro anti-tumor activity and mechanism. The in vivo anti-tumor activity of rAd-p53 combined with paclitaxel and cisplatin was evaluated with a C643 xenograft model. Intratumoral rAd-p53 was administered at a dose of 1×1010 VP/cm2 per 3 days for 8 times and intraperitoneal injection of Paclitaxel and cisplatin was administered at a dose of 5 mg/kg per 5 days for 4 times. The ATC patients received a pre-operative rAd-p53 therapy combined with chemotherapeutic treatment. rAd-p53 was injected intra-tumoral with 2-4×1012rAd-p53 viral particles (VP) per 3 days for 10 times. A cycle of chemotherapy including paclitaxel and cisplatin were also finished. Results: Both of MTT assay and C643 xenograft modelshowed rAd-P53 combined with paclitaxel and cisplatin significantly inhibited the growth of C643 tumors. And rAd-P53 displayed an enhanced sensitivity to chemotherapeutics. The in vitroexperiments demonstrated that rAd-P53 combined with paclitaxel and cisplatin did not only induce C643 cells apoptosis with DNA damage pathway but also inhibit cell metastasis via Raf-MEK-Erk pathway. 2 ATC patients who received rAd-p53 intratumoral injection and chemotherapy had a continued response (CR) and without evidence of distant metastasis after the combined treatment, then received surgery. All cases were followed up and the survival time for ATC patients was between 9-35 months. Conclusions: rAd-P53 combined with paclitaxel and cisplatin showed an enhanced sensitivity to chemotherapeutics to inhibit the tumor growth of C643 cells both in in vitro and in vivo. ATC patients receiving a pre-operative rAd-p53 therapy combined with chemotherapeutic treatment had a radical surgery and long-term survival. These results hinted that rAd-P53 combined with chemotherapeutics had a potential utility for the clinical treatment for ATC.

PCTAIRE3: a Putative Mediator of Growth Arrest and Death Induced by CTS-1, a Dominant-Positive P53-Derived Synthetic Tumor Suppressor, in Human Malignant Glioma Cells

Non-Immune-Mediated, p27-Associated, Growth Inhibition of Glioblastoma by Class-II-Transactivator (CIITA)

Inhibitory effects of adenovirus mediated Akt1 and PIK3R1 shRNA on the growth of malignant tumor cells in vitro and in vivo.

P53 Transcription-Dependent and -Independent Regulation of Cerebellar Neural Precursor Cell Apoptosis

Pten Restoration and Pik3cb Knockdown Synergistically Suppress Glioblastoma Growth in Vitro and in Xenografts

A novel approach to glioma therapy using an oncolytic adenovirus with two specific promoters.

Inhibitory Effects of Adenovirus Mediated Cox-2, Akt1 and Pik3r1 Shrna on the Growth of Malignant Tumor Cells in Vitro and in Vivo

A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers.

Effect of p53 targeting small molecule RITA combined with temozolomide on the growth of glioma cells in vitro

Integrated stress response (ISR) activation and apoptosis through HRI kinase by PG3 and other p53 pathway-restoring cancer therapeutics

STAT3-PTTG11 abrogation inhibits proliferation and induces apoptosis in malignant glioma cells.

Glioma Targeting Peptide in Combination with the P53 C Terminus Inhibits Glioma Cell Proliferation in Vitro

Integrated High Throughput Analysis Identifies GSK3 As a Crucial Determinant of P53-Mediated Apoptosis in Lung Cancer Cells

Inhibition of Glycolytic Metabolism in Glioblastoma Cells by Pt3glc Combinated with PI3K Inhibitor Via SIRT3-mediated Mitochondrial and PI3K/Akt-MAPK Pathway

Recombinant Human Adenovirus P53 Injection Enhanced Sensitivity Of Chemotherapeutics Through Dna Damage Response Pathway In Advanced Papillary Thyroid Cancer In Vitro And In Vivo

The Effects of combined therapy of Phosphatidylinositol 3p-Kinase inhibitor and Ad-PTEN in human glioma nude mice model

Recombinant Human Adenovirus P53 Injection (Rad-P53) is A Challenge for Anaplastic Thyroid Cancer Treatment

A Novel Tumor Suppressor Protein Encoded by Circular AKT3 RNA Inhibits Glioblastoma Tumorigenicity by Competing with Active Phosphoinositide-Dependent Kinase-1

PTEN and P27kip1 Have a Cooperative Role on Inhibition Proliferation,modulation of Cell Cycle and Inducing Apoptosis in Prostate Cancer PC-3 Cell

PIG3 Promotes NSCLC Cell Mitotic Progression and is Associated with Poor Prognosis of NSCLC Patients

SIRT1 promotes proliferation and inhibits apoptosis of human malignant glioma cell lines.